First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- ...

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the ...

Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune ... tumor responses achieved with PD-1/PD-L1 blockade alone.

With its combined immune and antiangiogenic mechanisms, ivonescimab offers a promising new ... Phase III success in lung cancer and its second head-to-head win over a PD-1 inhibitor.1 Currently, the ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...

HS1940 may broaden treatment options and improve outcomes across multiple types of cancer and may access receptor regions that other PD-1 inhibitors (e.g., nivolumab and pembrolizumab) may not reach.